Molecular determinants of loperamide and N-desmethyl loperamide binding in the hERG cardiac K+ channel.

Abuse of the common anti-diarrheal loperamide is associated with QT interval prolongation as well as development of the potentially fatal arrhythmia torsades de pointes. The mechanism underlying this cardiotoxicity is high affinity inhibition of the human ether-a-go-go-related gene (hERG) cardiac K+ channel. N-Desmethyl loperamide is the major metabolite of loperamide and is a close structural relative of the parent molecule. To date no information is available regarding the affinity of N-desmethyl loperamide for human cardiac ion channels. The effects of N-desmethyl loperamide on various cloned human cardiac ion channels including hERG, KvLQT1/mink and Nav1.5 were studied and compared to that of the parent. N-Desmethyl loperamide was a much weaker (7.5-fold) inhibitor of hERG compared to loperamide. However, given the higher plasma levels of the metabolite relative to the parent, it is likely that N-desmethyl loperamide can contribute, at least secondarily, to the cardiotoxicity observed with loperamide abuse. We used the recently solved cryo-EM structure of the hERG channel together with previously published inhibitors, to understand the basis of the interactions as well as the difference that a single methyl plays in the hERG channel blocking affinities of these two compounds.

[1]  R. Friesner,et al.  New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. , 2006, Bioorganic & medicinal chemistry.

[2]  T. Macgregor,et al.  Interaction of Ritonavir-Boosted Tipranavir with Loperamide Does Not Result in Loperamide-Associated Neurologic Side Effects in Healthy Volunteers , 2005, Antimicrobial Agents and Chemotherapy.

[3]  Yumi N Imai,et al.  Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach. , 2009, Journal of medicinal chemistry.

[4]  S. Borron,et al.  Intentional Misuse and Abuse of Loperamide: A New Look at a Drug with "Low Abuse Potential". , 2017, The Journal of emergency medicine.

[5]  M. Cook,et al.  Loperamide-Induced Torsades de Pointes: A Case Series. , 2017, The Journal of emergency medicine.

[6]  Kelly C. Chang,et al.  Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity. , 2017, Journal of pharmacological and toxicological methods.

[7]  State dependent dissociation of HERG channel inhibitors , 2007 .

[8]  Roy J. Vaz,et al.  Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic , 2016, Naunyn-Schmiedeberg's Archives of Pharmacology.

[9]  T. Flagg,et al.  Potent Inhibition of hERG Channels by the Over-the-Counter Antidiarrheal Agent Loperamide. , 2016, JACC Clinical Electrophysiology.

[10]  R. Friesner,et al.  Novel procedure for modeling ligand/receptor induced fit effects. , 2006, Journal of medicinal chemistry.

[11]  I. Papoutsis,et al.  “Poor man’s methadone” can kill the poor man. Extra-medical uses of loperamide: a review , 2017, Forensic Toxicology.

[12]  C. Wandel,et al.  Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.

[13]  Roderick MacKinnon,et al.  Cryo-EM Structure of the Open Human Ether-à-go-go-Related K+ Channel hERG , 2017, Cell.

[14]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Peter E. Wu,et al.  Clinical Review: Loperamide Toxicity , 2017, Annals of emergency medicine.

[16]  Nigel J Waters,et al.  Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. , 2008, Journal of pharmaceutical sciences.

[17]  S. Nattel An Emerging Malignant Arrhythmia Epidemic Due to Loperamide Abuse: Underlying Mechanisms and Clinical Relevance. , 2016, JACC. Clinical electrophysiology.